Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1781-1790
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1781
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1781
Table 3 Adverse events (n = 29)
| Grade 1 or 2 (%) | Grade 3 (%) | |
| Hematologic toxicities | ||
| Anemia | 3.85 | 0 |
| Leukopenia | 69.23 | 10.35 |
| Neutropenia | 61.54 | 6.9 |
| Thrombocytopenia | 15.4 | 0 |
| Non-hematologic toxicities | ||
| Decreased appetite | 13.79 | 0 |
| Fatigue | 13.79 | 0 |
| Radiation-induced esophagitis | 34.48 | 13.79 |
| Decreased body weight | 3.45 | 0 |
| Abnormal liver function | 3.45 | 0 |
- Citation: Yan MH, Liu F, Qu BL, Cai BN, Yu W, Dai XK. Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer. World J Gastrointest Oncol 2021; 13(11): 1781-1790
- URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1781.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1781